bullish

ENSC:画期的な鎮痛剤の第3相試験開始

302 Views17 Jul 2025 00:00
Issuer-paid
Ensysce Biosciences は、米国および世界中の他の先進国を悩ませているオピオイド危機の解決策を見つけることに取り組んでいます。
What is covered in the Full Insight:
  • Ensysce Biosciencesの紹介
  • PF614第3相試験開始
  • PF614とPF614-MPARの重要性
  • 財政的および制度的支援
  • 臨床試験データの示唆
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x